Ian Haydock (@ScripIanHaydock) header
Ian Haydock (@ScripIanHaydock) profile picture

Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.

Tokyo
Joined November 2012
Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)Photo by Ian Haydock (@ScripIanHaydock)
In this week's #podcast: Pfizer’s 2025 policy outlook; made in China blockbusters elusive; Vertex’s pain plans; Q3’s top 10 drugs; and sickle cell disease at ASH. Free access below. Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com//scrip…
1
1
3
290
Ian Haydock retweeted
Tanabe Shuts Down NeuroDerm, Along With Approved Parkinson’s Drug Decision resulted from “a comprehensive review of future strategy” and follows series of other divestment moves by Tanabe since Bain Capital acquisition. insights.citeline.com/scrip/…
1
44
This week: who’s setting the M&A pace this year; Roche’s pipeline reset; wet AMD market shakeup; Merck & Co. pulls I-DXd filing; and Merck withdraws Recarbio from the market (free accesss below): Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com/scrip/…
1
1
95
Ian Haydock retweeted
China’s National Medical Products Administration (NMPA) is outpacing the US Food and Drug Administration in the number of novel oncology medicines approved annually, but the FDA remains the leader in approving first-in-class medicines, a new analysis found insights.citeline.com/pink-s…
1
2
175
Ian Haydock retweeted
No Letup In Aging Japan’s Rising Health, Drug Costs Japan’s latest health and drug spending figures illustrate the dilemma of balancing drug pricing policy with the medical needs of a rapidly aging population. insights.citeline.com/pink-s…
1
1
46